Nike (NKE) shareholders have experienced sub-par total investment returns over the past 5 years (an average annual total return of ~7.3% versus ~11.4% for the S&P 500 when dividends are reinvested). NKE's average annual total return drops to (18.42%) versus ~2% for the S&P 500 if we change the timeframe to 2 years. Change the [...]
I consider low-risk Paychex (PAYX) to currently be attractively valued. I last reviewed this holding in my March 30, 2023 post at which time Q3 and YTD2023 results had just been released. With the release of its Q4 and FY2023 results and FY2024 outlook, I briefly revisit this holding. Business Overview Although I provide a [...]
I last reviewed Nasdaq, Inc. (NDAQ) in this October 21, 2021 post. Based on my analysis, I decided not to initiate a position. Fast forward to June 12, 2023. NDAQ has announced that it entered into a definitive agreement to acquire Adenza from Thoma Bravo for $10.5B in cash and shares of common stock; Adenza [...]
My Mastercard Is A Compelling Investment guest post at Dividend Power touches upon why it, and Visa (V), are my two largest holdings. While both Mastercard (MA) and V have been mandated by various jurisdictions to cap their interchange fees, I do not consider this as a reason to sour on either company; interchange fees [...]
Intact Financial (IFC.to) has attractive Total Shareholder Return (TSR) potential; it generated a ~14% Total Shareholder Return (TSR) from 2012 - 2022. While past results have no bearing on future results, IFC is a well-managed insurance company which leads me to believe it has a reasonable probability of generating a comparable return over the next [...]
I last reviewed Automatic Data Processing (ADP) in my January 26 post. Based on my analysis, I added a few additional shares at ~$225 in a retirement account where most of my ADP exposure is held; I do not disclose retirement account details. This explains why ADP was my 15th largest holding when I [...]
In my May 23 HEICO Corporation's (HEI and HEI.a) post, I disclose the purchase of 200 Class A non-voting shares @ ~$132/share. Upon further reflection, I have increased my HEICO exposure in the FFJ Portfolio with the purchase of another 100 shares at ~$127/share on May 26. This brings my exposure to 400 shares [...]
In this May 19, 2023 post, I disclose a new position in Thermo Fisher Scientific (TMO) with the purchase of 52 shares @ ~$515; I hold these shares in a 'Core' account within the FFJ Portfolio. On May 24, TMO held its 2023 Investor Day. Based on the information presented I acquired an additional [...]
HEICO Corporation's (HEI and HEI.a) total shareholder return over the past decade is very impressive. Although there is no assurance HEI can replicate what it has accomplished over the past decade, it has demonstrated that it has a winning formula. I am, therefore, willing to 'hitch my wagon to this horse'. Source: Tickertech.com [...]
In this May 10, 2023 Agilent Technologies (A) post, I disclose the addition of this Diagnostic & Research company to the FFJ Portfolio to go along with my exposure to Danaher Corporation (DHR); DHR posts are accessible through the Archives section of this site. I like the long-term outlook of the Diagnostic and Research industry. [...]